137 related articles for article (PubMed ID: 10430264)
21. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).
Kim SJ; Kim JW; Oh DY; Han SW; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
Am J Clin Oncol; 2012 Dec; 35(6):549-56. PubMed ID: 21659833
[TBL] [Abstract][Full Text] [Related]
22. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
23. Skeletal metastases of unknown origin. Diagnostic strategy for orthopedic surgeons.
Simon MA; Karluk MB
Clin Orthop Relat Res; 1982 Jun; (166):96-103. PubMed ID: 7083692
[TBL] [Abstract][Full Text] [Related]
24. [Survey for primary tumor site in patients with initial clinical presentation of bone metastasis].
Nakano S; Hasegawa Y; Ibuka K; Hashizume T; Noguchi A; Imaoka S; Komatsubara Y
Kaku Igaku; 1993 Sep; 30(9):1049-54. PubMed ID: 8230825
[TBL] [Abstract][Full Text] [Related]
25. Metastatic bone tumours.
Mysorekar VV; Dandekar CP; Rao SG
J Indian Med Assoc; 1998 Mar; 96(3):74-6. PubMed ID: 9828548
[TBL] [Abstract][Full Text] [Related]
26. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma.
Schapira DV; Jarrett AR
Arch Intern Med; 1995 Oct; 155(19):2050-4. PubMed ID: 7575063
[TBL] [Abstract][Full Text] [Related]
27. [Metastatic cáncer presentation. Validation of a diagnostic algorithm with 221 consecutive patients].
Losa Gaspà F; Germá JR; Albareda JM; Fernández-Ortega A; Sanjosé S; Fernández Trigo V
Rev Clin Esp; 2002 Jun; 202(6):313-9. PubMed ID: 12093395
[TBL] [Abstract][Full Text] [Related]
28. Bone metastases as the first manifestation of a tumour.
Barón MG; de la Gándara I; Espinosa E; de Paredes ML; Zamora P; Mondéjar JL
Int Orthop; 1991; 15(4):373-6. PubMed ID: 1725677
[TBL] [Abstract][Full Text] [Related]
29. Incidence, location, and diagnostic evaluation of metastatic bone disease.
Hage WD; Aboulafia AJ; Aboulafia DM
Orthop Clin North Am; 2000 Oct; 31(4):515-28, vii. PubMed ID: 11043092
[TBL] [Abstract][Full Text] [Related]
30. Immunocytochemical diagnosis of hepatocellular carcinoma and identification of carcinomas of unknown primary metastatic to the liver on fine-needle aspiration cytologies.
Onofre AS; Pomjanski N; Buckstegge B; Böcking A
Cancer; 2007 Aug; 111(4):259-68. PubMed ID: 17567831
[TBL] [Abstract][Full Text] [Related]
31. [Carcinoma of unknown primary. Case no. 5].
Long-Mira E
Ann Pathol; 2018 Jun; 38(3):185-187. PubMed ID: 29929746
[No Abstract] [Full Text] [Related]
32. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin.
Kaya AO; Coskun U; Unlu M; Akdemir UO; Ozdemir NY; Zengin N; Benekli M; Yildiz R; Yaman E; Ozturk B; Gumus M; Uner A; Yamac D; Ucgul E; Buyukberber S
Asian Pac J Cancer Prev; 2008; 9(4):683-6. PubMed ID: 19256759
[TBL] [Abstract][Full Text] [Related]
33. FDG PET and PET/CT for the detection of the primary tumour in patients with cervical non-squamous cell carcinoma metastasis of an unknown primary.
Paul SA; Stoeckli SJ; von Schulthess GK; Goerres GW
Eur Arch Otorhinolaryngol; 2007 Feb; 264(2):189-95. PubMed ID: 17177026
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
[TBL] [Abstract][Full Text] [Related]
35. Metastatic bone disease from occult carcinoma: a profile.
Nottebaert M; Exner GU; von Hochstetter AR; Schreiber A
Int Orthop; 1989; 13(2):119-23. PubMed ID: 2744913
[TBL] [Abstract][Full Text] [Related]
36. Bone metastases of unknown origin: epidemiology and principles of management.
Piccioli A; Maccauro G; Spinelli MS; Biagini R; Rossi B
J Orthop Traumatol; 2015 Jun; 16(2):81-6. PubMed ID: 25726410
[TBL] [Abstract][Full Text] [Related]
37. The role of fine-needle aspiration cytology in the evaluation of metastatic clear cell tumors.
Hughes JH; Jensen CS; Donnelly AD; Cohen MB; Silverman JF; Geisinger KR; Raab SS
Cancer; 1999 Dec; 87(6):380-9. PubMed ID: 10603192
[TBL] [Abstract][Full Text] [Related]
38. PET/CT in the management of metastatic cervical lymphadenopathy from unknown primary site: a seven years retrospective study.
Barbosa M; Duarte H; Breda E; Monteiro E
Rev Laryngol Otol Rhinol (Bord); 2013; 134(2):89-94. PubMed ID: 24683818
[TBL] [Abstract][Full Text] [Related]
39. [Metastases from cancers of unknown primary site. Data from 302 autopsies].
Le Cesne A; Le Chevalier T; Caille P; Cvitkovic E; Contesso G; Spielmann M; Rouesse J
Presse Med; 1991 Sep; 20(29):1369-73. PubMed ID: 1835011
[TBL] [Abstract][Full Text] [Related]
40. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy.
Miller FR; Karnad AB; Eng T; Hussey DH; Stan McGuff H; Otto RA
Head Neck; 2008 Jan; 30(1):28-34. PubMed ID: 17657782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
